Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  Akt inhibitor GSK2141795
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0001, NCI-2013-01354, NCI 9443, 9443, NCT01907815
Trametinib with or without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0229O, NCI-2013-01659, NCT01935973
Trametinib and GSK2141795 in Treating Patients With Stage III-IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC #13855, NCI-2013-01849, 13855, NCT01941927
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic, Persistent, or Recurrent Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-334, NCI-2013-02357, NCT01958112
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic Triple-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 13117, NCI-2013-01895, 2013C0069, NCI 9455, 9455, NCT01964924
Trametinib with or without GSK2141795 in Treating Patients with Metastatic Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-144, NCI-2013-02091, 9445, NCT01979523
Trametinib and Akt inhibitor GSK2141795 in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHL-091, NCI-2013-02148, NCI 9460, NCT01951495, 9460, NCT01989598
Start Over